Tonix Pharmaceuticals Announces Preliminary Q1 2026 Results and TONMYA Revenue Growth

Tonix Pharmaceuticals Holding Corp. reported preliminary financial results for the first quarter ended March 31, 2026. The company reported total net product revenue of approximately $6.9 million, a significant increase from $2.4 million in the same period last year. This growth was driven by $3.7 million in sales from TONMYA®, which launched in November 2025, alongside $3.2 million from Zembrace® SymTouch® and Tosymra®. Despite the revenue growth, the company reported a preliminary net loss of approximately $40.8 million for the quarter, compared to $16.8 million in Q1 2025. Net cash used in operating activities rose to $40.2 million. As of March 31, 2026, Tonix held approximately $185.5 million in cash and cash equivalents. Including $17.4 million raised through equity offerings in early Q2 2026, the company anticipates its cash runway will fund operations into the second quarter of 2027. The company expects to file its full Quarterly Report on Form 10-Q on or about May 11, 2026.